RedHill Biopharma

21 Ha’arba’a Street
Tel-Aviv
64739
United States

Tel: 972-0-3-541-3131
Fax: 972-0-3-541-3144

Email: info@redhillbio.com

Show jobs for this employer

367 articles with RedHill Biopharma

  • The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and Mexico

  • Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In addition, the publication highlights that elevated baseline C-reactive protein (CRP) may be used to identify treatment responders in this complex disease, which lacks reliable predictive markers --  T

  • Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori toclarithromycin-based therapies

  • Phase 2/3 study process initiated in Brazil and Mexico  The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia   Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites   Potential submission of emergency use applications planned for Q4/2020   Enrollment in parallel U.S. Phase 2 study in severe COVID-19 patients expected to be completed in August TEL-AVIV, Israel and

  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced it is seeking regulatory review by the Securities and Exchange Commission, and intends to approach the Financial Industry Regulatory Authority, Inc., regarding suspicious trading activity including potential naked short selling of the Company’s stock.

  • Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later this month with potential submission of Emergency Use Authorization application planned for Q4/2020 -- In parallel, the U.S. Phase 2a study with opaganib in patients with severe COVID-19 is ad

  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 development programs with opaganib 1 and RHB-107 2 for COVID-19 at the Sachs Digital Novel Coronavirus Investment Forum, taking place July 7-9, 2020.

  • The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy, Russia and additional countries  -- In parallel, a U.S. study with opaganib in up to 40 severe COVID-19 patients has been initiated at leading medical centers TEL-AVIV, Israel and RALEIGH, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or

  • Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has submitted Clinical Trial Applications (CTA) with the UK Medicines & Healthcare Products Regulatory Agency (MHRA) and the Italian Medicines Agency (AIFA) for a Phase 2/3 clinical study evaluating opaganib (Yeliva®, ABC294640)

  • The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 patients is being initiated in the U.S. TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a s

  • RedHill Biopharma Ltd. announced that Mr. Gilead Raday, RedHill’s Chief Operating Officer, will present the Company’s development program with opaganib 1 for COVID-19, as well as the Phase 3 development program with RHB-204 for pulmonary nontuberculous mycobacteria infections, at the MedInvest Virtual Infectious Diseases and Immunology Conference on Monday, June 15, 2020, at 12:40 p.m. EDT.

  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill’s Senior Vice President Business Development and Licensing, will present a corporate overview at BIO Digital, taking place June 8-12, 2020. The presentation will be available during the conference on-demand via https://www.bio.org/events/bio-digital/sessions/658958

  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 11:00 a.m. EDT . The presentation will be broadcast live and available via replay for 30 days on the Company's website, htt

  • Completed acquisition of Movantik® from AstraZeneca on April 1, 2020, and initiated U.S. promotion with net revenues of $7.3 million in April

  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020.

  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020, at 7:30 a.m. EDT.

  • It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
  • The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S.  -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged from the hospital  -- Opaganib’s unique mechanism of action has both anti-inflammatory and anti-viral activities, targeting a critical host factor, minimizing potential development of resistance du